You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethylprednisolone
Accession NumberDB00959  (APRD00342)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

A prednisolone derivative with similar anti-inflammatory action. [PubChem]

Structure
Thumb
Synonyms
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
delta(1)-6alpha-Methylhydrocortisone
Medrate
Medrol
Medrone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Metilprednisolona
Solomet
Urbason
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Depo-medrolinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissuePharmacia and Upjohn Company1959-05-28Not applicableUs
Depo-medrolinjection, suspension40 mg/mLintramuscularREMEDYREPACK INC.2013-06-11Not applicableUs
Depo-medrolinjection, suspension80 mg/mLintralesional; intramuscular; intrasynovial; soft tissueDispensing Solutions, Inc.1959-05-28Not applicableUs
Depo-medrolinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissueRebel Distributors Corp1959-05-28Not applicableUs
Depo-medrolinjection, suspension80 mg/mLintramuscularREMEDYREPACK INC.2014-09-12Not applicableUs
Depo-medrolinjection, suspension80 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia And Upjohn Company Llc1959-05-28Not applicableUs
Depo-medrolinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia And Upjohn Company Llc1959-05-28Not applicableUs
Depo-medrolinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; soft tissueCardinal Health1959-05-28Not applicableUs
Depo-medrolinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; soft tissuePharmacia and Upjohn Company1959-05-28Not applicableUs
Depo-medrolinjection, suspension40 mg/1intramuscularREMEDYREPACK INC.2013-04-10Not applicableUs
Depo-medrolinjection, suspension20 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia And Upjohn Company Llc1959-05-28Not applicableUs
Depo-medrolinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissueCardinal Health1959-05-28Not applicableUs
Depo-medrol (with Preservative) 20 mg/mlsuspension20 mgintra-articular; intralesional; intramuscular; intrasynovialPfizer Canada Inc1995-12-31Not applicableCanada
Depo-medrol (with Preservative) 40 mg/mlsuspension40 mgintra-articular; intralesional; intramuscular; intrasynovialPfizer Canada Inc1994-12-31Not applicableCanada
Depo-medrol (with Preservative) 80 mg/mlsuspension80 mgintra-articular; intralesional; intramuscular; intrasynovialPfizer Canada Inc1994-12-31Not applicableCanada
Depo-medrol 40 mg/mlsuspension40 mgintra-articular; intralesional; intramuscular; intrasynovialPfizer Canada Inc1960-12-31Not applicableCanada
Depo-medrol 80 mg/mlsuspension80 mgintra-articular; intralesional; intramuscular; intrasynovialPfizer Canada Inc1969-12-31Not applicableCanada
Medroltablet16 mg/1oralPharmacia And Upjohn Company Llc1957-10-24Not applicableUs
Medroltablet4 mg/1oralPharmacia And Upjohn Company Llc1957-10-24Not applicableUs
Medroltablet32 mg/1oralREMEDYREPACK INC.2011-10-11Not applicableUs
Medroltablet2 mg/1oralPharmacia And Upjohn Company Llc1957-10-24Not applicableUs
Medroltablet4 mg/1oralA S Medication Solutions Llc1957-10-24Not applicableUs
Medroltablet8 mg/1oralPharmacia And Upjohn Company Llc1957-10-24Not applicableUs
Medroltablet4 mg/1oralStat Rx USA1957-10-24Not applicableUs
Medroltablet2 mg/1oralPharmacia And Upjohn Company Llc2013-09-20Not applicableUs
Medroltablet4 mg/1oralA S Medication Solutions Llc1957-10-24Not applicableUs
Medroltablet4 mg/1oralREMEDYREPACK INC.2013-02-19Not applicableUs
Medroltablet32 mg/1oralPharmacia And Upjohn Company Llc1957-10-24Not applicableUs
Medrol 16 mgtablet16 mgoralPfizer Canada Inc1968-12-31Not applicableCanada
Medrol 4 mgtablet4 mgoralPfizer Canada Inc1960-12-31Not applicableCanada
Medrol Topical 0.25%cream2.5 mgtopicalPfizer Canada Inc1960-12-312006-08-02Canada
Methylprednisolonetablet8 mg/1oralGreenstone LLC2013-03-25Not applicableUs
Methylprednisolonetablet32 mg/1oralGreenstone LLC2013-03-25Not applicableUs
Methylprednisolonetablet4 mg/1oralKeltman Pharmaceuticals Inc.2007-09-14Not applicableUs
Methylprednisolonetablet4 mg/1oralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
Methylprednisolonetablet4 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-02-09Not applicableUs
Methylprednisolonetablet16 mg/1oralGreenstone LLC2013-03-25Not applicableUs
Methylprednisolonetablet4 mg/1oralGreenstone LLC2011-10-11Not applicableUs
Methylprednisolone Acetate Injectable Suspension USPsuspension80 mgintra-articular; intramuscular; intrasynovial; soft tissue injectionSandoz Canada Incorporated2003-04-04Not applicableCanada
Methylprednisolone Acetate Injectable Suspension USPsuspension40 mgintra-articular; intramuscular; intrasynovial; soft tissue injectionSandoz Canada Incorporated2003-03-28Not applicableCanada
Methylprednisolone Acetate Injectable Suspension USP -(80mg/ml With Preservative)suspension80 mgintra-articular; intramuscular; intrasynovial; soft tissue injectionSandoz Canada Incorporated2003-04-10Not applicableCanada
Methylprednisolone Acetate Injectable Suspension USP -(40mg/ml With Preservative)suspension40 mgintra-articular; intramuscular; intrasynovial; soft tissue injectionSandoz Canada Incorporated2003-04-10Not applicableCanada
Methylprednisolone Sodium Succinate for Injectionpowder for solution125 mgintramuscular; intravenousTeva Canada Limited2000-03-01Not applicableCanada
Methylprednisolone Sodium Succinate for Injectionpowder for solution5 gintramuscular; intravenousTeva Canada LimitedNot applicableNot applicableCanada
Methylprednisolone Sodium Succinate for Injectionpowder for solution1 gintramuscular; intravenousTeva Canada Limited2000-03-01Not applicableCanada
Methylprednisolone Sodium Succinate for Injectionpowder for solution40 mgintramuscular; intravenousTeva Canada Limited2000-03-01Not applicableCanada
Methylprednisolone Sodium Succinate for Injectionpowder for solution500 mgintramuscular; intravenousTeva Canada Limited2000-03-01Not applicableCanada
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-04-01Not applicableUs
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolkit; powder for solution125 mgintramuscular; intravenousPfizer Canada Inc1997-06-102005-08-05Canada
Solu-medrolinjection, powder, for solution500 mg/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, lyophilized, for solution40 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
Solu-medrolpowder, for solution125 mg/mLintravenousREMEDYREPACK INC.2011-12-19Not applicableUs
Solu-medrolkit; powder for solution1 gintramuscular; intravenousPfizer Canada Inc1971-12-31Not applicableCanada
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution40 mg/1intravenousREMEDYREPACK INC.2013-04-15Not applicableUs
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolkit; powder500 mgintramuscular; intravenousPfizer Canada Inc1995-12-312015-09-15Canada
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution1 g/1intravenousREMEDYREPACK INC.2013-02-09Not applicableUs
Solu-medrolkit; powder for solution1 gintramuscular; intravenousPfizer Canada Inc2012-02-07Not applicableCanada
Solu-medrolinjection, powder, for solution1 g/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolkit; powder1 gintramuscular; intravenousPfizer Canada Inc1994-12-312015-09-15Canada
Solu-medrolkit; powder for solution500 mgintramuscular; intravenousPfizer Canada Inc2012-01-18Not applicableCanada
Solu-medrolinjection, powder, for solution500 mg/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolkit; powder40 mgintramuscular; intravenousPfizer Canada Inc1994-12-312015-09-15Canada
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousA S Medication Solutions Llc1959-04-02Not applicableUs
Solu-medrolkit; powder for solution125 mgintramuscular; intravenousPfizer Canada Inc2012-01-18Not applicableCanada
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousUs Med Source, Llc2014-07-18Not applicableUs
Solu-medrolkit; powder125 mgintramuscular; intravenousPfizer Canada Inc1994-12-312015-09-15Canada
Solu-medrolkit; powder for solution40 mgintramuscular; intravenousPfizer Canada Inc2012-01-11Not applicableCanada
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-04-01Not applicableUs
Solu-medrolinjection, powder, for solution1 g/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolkit; powder for solution40 mgintramuscular; intravenousPfizer Canada Inc1997-06-102005-08-05Canada
Solu-medrolkitPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, lyophilized, for solution125 mg/2mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
Solu-medrolkit; powder for solution500 mgintramuscular; intravenousPfizer Canada Inc1970-12-31Not applicableCanada
Solumedrol Inj 125mg Sterile Mixovialpowder for solution125 mgintramuscular; intravenous; rectalThe Upjohn Company Of Canada1969-12-311996-09-10Canada
Solumedrol Inj 40mg Sterile Mixovialpowder for solution40 mgintramuscular; intravenous; rectalThe Upjohn Company Of Canada1964-12-311996-09-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
A-methapredinjection, powder, lyophilized, for solution125 mg/2mLintramuscular; intravenousHospira, Inc.2005-12-20Not applicableUs
A-methapredinjection, powder, lyophilized, for solution40 mg/mLintramuscular; intravenousHospira, Inc.2005-12-20Not applicableUs
Methylprednisolonetablet4 mg/1oralPhysicians Total Care, Inc.2009-10-15Not applicableUs
Methylprednisolonetablet4 mg/1oralSandoz Inc1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralRebel Distributors Corp.1997-10-31Not applicableUs
Methylprednisolonetablet16 mg/1oralKAISER FOUNDATION HOSPITALS2012-09-12Not applicableUs
Methylprednisolonetablet4 mg/1oralDispensing Solutions, Inc.1998-12-22Not applicableUs
Methylprednisolonetablet4 mg/1oralREMEDYREPACK INC.2012-09-05Not applicableUs
Methylprednisolonetablet4 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralA S Medication Solutions1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralSTAT Rx USA LLC1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralClinical Solutions Wholesale1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralPreferred Pharmaceuticals, Inc.2014-10-08Not applicableUs
Methylprednisolonetablet4 mg/1oralA S Medication Solutions Llc1998-12-22Not applicableUs
Methylprednisolonetablet4 mg/1oralProficient Rx LP1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralLake Erie Medical DBA Quality Care Products LLC1998-12-22Not applicableUs
Methylprednisolonetablet4 mg/1oralPreferred Pharmaceuticals, Inc.2013-09-03Not applicableUs
Methylprednisolonetablet4 mg/1oralBreckenridge Pharmaceutical, Inc.2003-11-07Not applicableUs
Methylprednisolonetablet4 mg/1oralDIRECT RX2014-01-01Not applicableUs
Methylprednisolonetablet4 mg/1oralAidarex Pharmaceuticals LLC1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralQualitest Pharmaceuticals1998-12-22Not applicableUs
Methylprednisolonetablet4 mg/1oralAmerican Health Packaging2013-11-25Not applicableUs
Methylprednisolonetablet4 mg/1oralUnit Dose Services1997-10-31Not applicableUs
Methylprednisolonetablet32 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralBlue Point Laboratories2013-08-02Not applicableUs
Methylprednisolonetablet4 mg/1oralREMEDYREPACK INC.2012-07-10Not applicableUs
Methylprednisolonetablet16 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralPhysicians Total Care, Inc.1994-11-29Not applicableUs
Methylprednisolonetablet4 mg/1oralSTAT Rx USA LLC1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralbryant ranch prepack1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralREMEDYREPACK INC.2012-03-01Not applicableUs
Methylprednisolonetablet8 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissueTeva Parenteral Medicines, Inc.2006-10-31Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintramuscular; intrasynovial; soft tissuePhysicians Total Care, Inc.2012-07-26Not applicableUs
Methylprednisolone Acetateinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; soft tissueSandoz Inc2009-01-29Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissueProficient Rx LP2005-03-08Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissueTeva Parenteral Medicines, Inc.2006-10-31Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissueSandoz Inc2009-01-29Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissueTeva Parenteral Medicines, Inc.2005-03-08Not applicableUs
Methylprednisolone Acetateinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; parenteral; soft tissueSandoz Inc2009-03-05Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; parenteral; soft tissueSandoz Inc2009-03-05Not applicableUs
Methylprednisolone Acetateinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; parenteral; soft tissueRebel Distributors Corp2009-03-05Not applicableUs
Methylprednisolone Acetateinjection, suspension80 mg/mLintralesional; intramuscular; intrasynovial; soft tissueTeva Parenteral Medicines, Inc.2006-10-31Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; parenteral; soft tissueRebel Distributors Corp2009-03-05Not applicableUs
Methylprednisolone Acetateinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; soft tissueTeva Parenteral Medicines, Inc.2005-03-08Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution40 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2004-11-30Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution1 g/16mLintramuscular; intravenousFresenius Kabi USA, LLC2004-11-30Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution2 g/1intramuscular; intravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution500 mg/1intramuscular; intravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution125 mg/1intramuscular; intravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution125 mg/2mLintramuscular; intravenousCardinal Health2004-11-30Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution125 mg/2mLintramuscular; intravenousFresenius Kabi USA, LLC2004-11-30Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution40 mg/1intramuscular; intravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution40 mg/mLintramuscular; intravenousCardinal Health2004-11-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hybrisilgel10 mg/gtopicalBio Zone Laboratories, Inc.2010-05-05Not applicableUs
International Brands
NameCompany
MedrateNot Available
MedroneNot Available
MeproloneNot Available
SolometNot Available
UrbasonNot Available
Brand mixtures
NameLabellerIngredients
Depo-medrol With LidocainePfizer Canada Inc
Medrol Acne LotionPfizer Canada Inc
Methylprednisolone Sodium Succinate for Injection, USPHospira Healthcare Corporation
Neo-medrolPfizer Canada Inc
Neo-medrol Acne LotionPfizer Canada Inc
Physicians Ez Use M-predProficient Rx LP
Readysharp-p40Terrain Pharmaceuticals
Readysharp-p80Terrain Pharmaceuticals
Salts
Name/CASStructureProperties
Methylprednisolone acetate
ThumbNot applicableDBSALT001157
Methylprednisolone sodium succinate
ThumbNot applicableDBSALT001158
Categories
UNIIX4W7ZR7023
CAS number83-43-2
WeightAverage: 374.4706
Monoisotopic: 374.20932407
Chemical FormulaC22H30O5
InChI KeyInChIKey=VHRSUDSXCMQTMA-PJHHCJLFSA-N
InChI
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
IUPAC Name
(1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])C[[email protected]](C)C2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationAdjunctive therapy for short-term administration in rheumatoid arthritis.
PharmacodynamicsMethylprednisolone and its derivatives, methylprednisolone sodium succinate and methylprednisolone acetate, are synthetic glucocorticoids used as antiinflammatory or immunosuppressive agents.
Mechanism of actionUnbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Related Articles
AbsorptionOral bioavailability 80-99%
Volume of distributionNot Available
Protein binding78%
Metabolism

Hepatic

Route of eliminationNot Available
Half life1-3 hours
ClearanceNot Available
ToxicityLD50=2000 mg/kg (orally in rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9911
Blood Brain Barrier+0.9484
Caco-2 permeable-0.6404
P-glycoprotein substrateSubstrate0.7812
P-glycoprotein inhibitor INon-inhibitor0.7489
P-glycoprotein inhibitor IINon-inhibitor0.604
Renal organic cation transporterNon-inhibitor0.769
CYP450 2C9 substrateNon-substrate0.8415
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7582
CYP450 1A2 substrateNon-inhibitor0.9473
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9513
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9167
Ames testNon AMES toxic0.9337
CarcinogenicityNon-carcinogens0.9529
BiodegradationNot ready biodegradable0.9492
Rat acute toxicity2.0025 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9459
hERG inhibition (predictor II)Non-inhibitor0.5985
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Cadista pharmaceuticals inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Heather drug co inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Abbott laboratories hosp products div
  • Hemopharm usa corp
  • Hospira inc
  • Elkins sinn div ah robins co inc
  • Organon usa inc
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Bedford laboratories
  • International medication systems ltd
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintramuscular; intravenous125 mg/2mL
Injection, powder, lyophilized, for solutionintramuscular; intravenous40 mg/mL
Injection, suspensionintra-articular; intralesional; intramuscular; soft tissue40 mg/mL
Injection, suspensionintra-articular; intralesional; intramuscular; soft tissue80 mg/mL
Injection, suspensionintralesional; intramuscular; intrasynovial; soft tissue20 mg/mL
Injection, suspensionintramuscular40 mg/1
Injection, suspensionintramuscular40 mg/mL
Injection, suspensionintramuscular80 mg/mL
Suspensionintra-articular; intralesional; intramuscular; intrasynovial20 mg
Suspensionintra-articular; intralesional; intramuscular; intrasynovial80 mg
Suspensionintra-articular; intralesional; intramuscular; intrasynovial40 mg
Solutionintra-articular; intrabursal
Geltopical10 mg/g
Tabletoral2 mg/1
Tabletoral32 mg/1
Tabletoral16 mg
Tabletoral4 mg
Creamtopical2.5 mg
Tabletoral16 mg/1
Tabletoral4 mg/1
Tabletoral8 mg/1
Injection, suspensionintra-articular; intralesional; intramuscular; parenteral; soft tissue40 mg/mL
Injection, suspensionintra-articular; intralesional; intramuscular; parenteral; soft tissue80 mg/mL
Injection, suspensionintralesional; intramuscular; intrasynovial; soft tissue40 mg/mL
Injection, suspensionintralesional; intramuscular; intrasynovial; soft tissue80 mg/mL
Injection, suspensionintramuscular; intrasynovial; soft tissue40 mg/mL
Suspensionintra-articular; intramuscular; intrasynovial; soft tissue injection40 mg
Suspensionintra-articular; intramuscular; intrasynovial; soft tissue injection80 mg
Injection, powder, lyophilized, for solutionintramuscular; intravenous1 g/16mL
Injection, powder, lyophilized, for solutionintramuscular; intravenous125 mg/1
Injection, powder, lyophilized, for solutionintramuscular; intravenous2 g/1
Injection, powder, lyophilized, for solutionintramuscular; intravenous40 mg/1
Injection, powder, lyophilized, for solutionintramuscular; intravenous500 mg/1
Powder for solutionintramuscular; intravenous1 g
Powder for solutionintramuscular; intravenous125 mg
Powder for solutionintramuscular; intravenous40 mg
Powder for solutionintramuscular; intravenous5 g
Powder for solutionintramuscular; intravenous500 mg
Powder for solutionintramuscular; intravenous
Creamtopical
Lotiontopical
Kit
Kitepidural; infiltration; intramuscular; intrasynovial; soft tissue; topical
Kitepidural; infiltration; intra-articular; intralesional; intramuscular; soft tissue
Injection, powder, for solutionintramuscular; intravenous1 g/mL
Injection, powder, for solutionintramuscular; intravenous125 mg/mL
Injection, powder, for solutionintramuscular; intravenous40 mg/mL
Injection, powder, for solutionintramuscular; intravenous500 mg/mL
Injection, powder, for solutionintravenous1 g/1
Injection, powder, for solutionintravenous40 mg/1
Kit
Kit; powderintramuscular; intravenous1 g
Kit; powderintramuscular; intravenous125 mg
Kit; powderintramuscular; intravenous40 mg
Kit; powderintramuscular; intravenous500 mg
Kit; powder for solutionintramuscular; intravenous1 g
Kit; powder for solutionintramuscular; intravenous125 mg
Kit; powder for solutionintramuscular; intravenous40 mg
Kit; powder for solutionintramuscular; intravenous500 mg
Powder, for solutionintravenous125 mg/mL
Powder for solutionintramuscular; intravenous; rectal125 mg
Powder for solutionintramuscular; intravenous; rectal40 mg
Prices
Unit descriptionCostUnit
Methylprednisolone powder96.25USD g
Methylprednisolone ac powdr40.09USD g
Methylprednisolone ss 1 gm vial31.2USD vial
Solu-medrol 1 gm vial24.43USD vial
Solu-medrol (pf) 500 mg vial20.9USD vial
MethylPREDNISolone (Pak) 21 4 mg tablet Disp Pack16.99USD disp
Methylprednisolone 500 mg vial15.6USD vial
Solu-medrol 500 mg vial12.9USD vial
Depo-medrol 80 mg/ml vial11.67USD ml
Methylprednisolone 125 mg vial10.0USD vial
Methylprednisolone 80 mg/ml vial9.12USD ml
Depo-medrol 40 mg/ml vial6.41USD ml
Solu-medrol (pf) 125 mg vial5.83USD vial
Methylprednisolone 40 mg/ml vial5.22USD ml
Medrol 32 mg tablet5.13USD tablet
Methylprednisolone 32 mg tablet4.62USD tablet
Depo-medrol 20 mg/ml vial3.78USD ml
Methylprednisolone 16 mg tablet3.17USD tablet
Methylprednisolone 40 mg vial3.0USD vial
A-methapred 40 mg vial2.36USD vial
Medrol 16 mg tablet2.28USD tablet
Medrol 8 mg tablet2.23USD tablet
Methylprednisolone 8 mg tablet1.74USD tablet
Methylprednisolone 4 mg tablet1.68USD tablet
Medrol 4 mg dosepak1.59USD each
Medrol 4 mg tablet0.99USD tablet
Medrol 2 mg tablet0.84USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point232.5 °CPhysProp
water solubility120 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.5Not Available
logS-2.99ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.109 mg/mLALOGPS
logP2.06ALOGPS
logP1.56ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity103.04 m3·mol-1ChemAxon
Polarizability40.84 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Klaus Annen, Karl Petzoldt, Henry Laurent, Rudolf Wiechert, Helmut Hofmeister, “Novel 6.alpha.-methylprednisolone derivatives, their preparation, and their use.” U.S. Patent US4587236, issued March, 1973.

US4587236
General References
  1. Sloka JS, Stefanelli M: The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005 Aug;11(4):425-32. [PubMed:16042225 ]
External Links
ATC CodesS01CA08D07CA02D10AA02H02AB04D07AA01H02BX01
AHFS Codes
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (244 KB)
MSDSDownload (72.6 KB)
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methylprednisolone.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methylprednisolone.
AldesleukinMethylprednisolone may decrease the antineoplastic activities of Aldesleukin.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methylprednisolone.
Aluminum hydroxideThe bioavailability of Methylprednisolone can be decreased when combined with Aluminum hydroxide.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Methylprednisolone.
Amphotericin BMethylprednisolone may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Methylprednisolone can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Methylprednisolone can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Methylprednisolone.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Methylprednisolone.
BoceprevirThe serum concentration of Methylprednisolone can be increased when it is combined with Boceprevir.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Methylprednisolone.
Calcium carbonateThe bioavailability of Methylprednisolone can be decreased when combined with Calcium carbonate.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methylprednisolone.
CapromabMethylprednisolone may decrease effectiveness of Capromab as a diagnostic agent.
CarbamazepineThe serum concentration of Methylprednisolone can be decreased when it is combined with Carbamazepine.
CeritinibThe serum concentration of Methylprednisolone can be increased when it is combined with Ceritinib.
ChlorotrianiseneThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorotrianisene.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methylprednisolone.
ClarithromycinThe serum concentration of Methylprednisolone can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Methylprednisolone can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin can be decreased when used in combination with Methylprednisolone.
CyclosporineThe serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.
DarunavirThe serum concentration of Methylprednisolone can be increased when it is combined with Darunavir.
DeferasiroxThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Deferasirox.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Methylprednisolone.
DesmopressinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Desmopressin.
DihydrotestosteroneMethylprednisolone may increase the fluid retaining activities of Dihydrotestosterone.
EnzalutamideThe serum concentration of Methylprednisolone can be decreased when it is combined with Enzalutamide.
FosaprepitantThe serum concentration of Methylprednisolone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Methylprednisolone can be decreased when it is combined with Fosphenytoin.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Methylprednisolone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methylprednisolone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methylprednisolone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Methylprednisolone.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methylprednisolone.
IcosapentThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Icosapent.
IdelalisibThe serum concentration of Methylprednisolone can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Methylprednisolone.
IndinavirThe serum concentration of Methylprednisolone can be increased when it is combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methylprednisolone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methylprednisolone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methylprednisolone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methylprednisolone.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Methylprednisolone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methylprednisolone.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Methylprednisolone.
ItraconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Ketoconazole.
LeflunomideThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Leflunomide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Methylprednisolone.
Magnesium oxideThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone.
MifepristoneThe therapeutic efficacy of Methylprednisolone can be decreased when used in combination with Mifepristone.
MitotaneThe serum concentration of Methylprednisolone can be decreased when it is combined with Mitotane.
NatalizumabThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab.
NefazodoneThe serum concentration of Methylprednisolone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Methylprednisolone can be increased when it is combined with Nelfinavir.
NicorandilThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nicorandil.
OxandroloneMethylprednisolone may increase the fluid retaining activities of Oxandrolone.
PhenobarbitalThe serum concentration of Methylprednisolone can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Methylprednisolone can be decreased when it is combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methylprednisolone.
PosaconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Methylprednisolone can be decreased when it is combined with Primidone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Methylprednisolone.
RifabutinThe serum concentration of Methylprednisolone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Methylprednisolone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Methylprednisolone can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Methylprednisolone can be increased when it is combined with Ritonavir.
RoflumilastRoflumilast may increase the immunosuppressive activities of Methylprednisolone.
SaquinavirThe serum concentration of Methylprednisolone can be increased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methylprednisolone.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methylprednisolone.
SparfloxacinThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Sparfloxacin.
TacrineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Methylprednisolone.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Methylprednisolone.
TelithromycinThe serum concentration of Methylprednisolone can be increased when it is combined with Telithromycin.
TestosteroneMethylprednisolone may increase the fluid retaining activities of Testosterone.
TofacitinibMethylprednisolone may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methylprednisolone.
TorasemideMethylprednisolone may increase the hypokalemic activities of Torasemide.
TrastuzumabTrastuzumab may increase the neutropenic activities of Methylprednisolone.
TrichlormethiazideMethylprednisolone may increase the hypokalemic activities of Trichlormethiazide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methylprednisolone.
VoriconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Voriconazole.
WarfarinMethylprednisolone may increase the anticoagulant activities of Warfarin.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Owen HC, Miner JN, Ahmed SF, Farquharson C: The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):164-70. Epub 2006 Dec 19. [PubMed:17182172 ]
  2. Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM: Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl). 2006 Dec;189(2):225-35. Epub 2006 Oct 3. [PubMed:17016711 ]
  3. Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY: Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G590-8. Epub 2006 Oct 26. [PubMed:17068119 ]
  4. Quesnell RR, Han X, Schultz BD: Glucocorticoids stimulate ENaC upregulation in bovine mammary epithelium. Am J Physiol Cell Physiol. 2007 May;292(5):C1739-45. Epub 2007 Jan 24. [PubMed:17251323 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Oka A, Oda M, Saitoh H, Nakayama A, Takada M, Aungst BJ: Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6. [PubMed:11913542 ]
  2. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  3. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23